BRPI0419067A - método para aumento da cognição utilizando ziprasidona - Google Patents

método para aumento da cognição utilizando ziprasidona

Info

Publication number
BRPI0419067A
BRPI0419067A BRPI0419067-0A BRPI0419067A BRPI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A
Authority
BR
Brazil
Prior art keywords
mammal
ziprasidone
formula
compound
human
Prior art date
Application number
BRPI0419067-0A
Other languages
English (en)
Inventor
Steven Joseph Romano
Rachel Heather Swift
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0419067A publication Critical patent/BRPI0419067A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

MéTODO PARA AUMENTO DA COGNIçãO UTILIZANDO ZIPRASIDONA. A presente invenção, em um aspecto, refere-se a um método para utilização de compostos heterocíclicos de piperazinil, de fórmula I, tal como definida abaixo, para aumento da cognição em um mamífero, incluindo um ser humano, por exemplo um mamífero afetado com psicose, autismo, demência ou retardo mental, compreendendo a administração, ao mamífero, de uma quantidade eficaz de um composto de fórmula I (por exemplo, ziprasidona). Em um outro aspecto, a presente invenção é direcionada para um método de redução ou melhoria, em um mamífero, incluindo um ser humano, afetado com um distúrbio ou condição selecionado a partir de autismo, retardo mental, distúrbio obsessivo-compulsivo e demência, sintomas positivos (por exemplo, agressividade excessiva, comportamento sexual desinibido, comportamento sexual inadequado, agitação, comportamento compulsivo, tal como bater a cabeça, morder os lábios, auto-mutilação ou comportamento estereotipado) associados com os distúrbios ou condições acima referidos, método esse que compreende a administração, ao mamífero, de uma quantidade eficaz de um composto de fórmula I (por exemplo, ziprasidona). Em um outro aspecto, a presente invenção é direcionada para um método de tratamento do distúrbio bipolar pediátrico em um mamífero, incluindo um ser humano, método esse que compreende a administração, ao mamífero, de uma quantidade eficaz de um composto de fórmula I (por exemplo, ziprasidona). Os compostos do composto de fórmula I são definidos como se segue: ou um sal de adição de ácido farmaceuticamente aceitável do mesmo, em que Ar, n, X e Y são como definidos.
BRPI0419067-0A 2003-05-16 2004-05-05 método para aumento da cognição utilizando ziprasidona BRPI0419067A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47137903P 2003-05-16 2003-05-16
PCT/IB2004/001600 WO2004100956A1 (en) 2003-05-16 2004-05-05 Method for enhancing cognition using ziprasidone

Publications (1)

Publication Number Publication Date
BRPI0419067A true BRPI0419067A (pt) 2007-12-11

Family

ID=33452442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0419067-0A BRPI0419067A (pt) 2003-05-16 2004-05-05 método para aumento da cognição utilizando ziprasidona

Country Status (9)

Country Link
US (2) US20050014764A1 (pt)
EP (1) EP1626722A1 (pt)
JP (1) JP2006528236A (pt)
AR (1) AR044337A1 (pt)
BR (1) BRPI0419067A (pt)
CA (2) CA2625837A1 (pt)
MX (1) MXPA05012325A (pt)
TW (1) TW200507847A (pt)
WO (1) WO2004100956A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408976B3 (en) 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US20100222353A1 (en) * 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
EP1988077A4 (en) * 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008046046A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
CN103497114A (zh) * 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
AU2009244082A1 (en) * 2008-05-09 2009-11-12 Emory University NMDA receptor antagonists for the treatment of neuropsychiatric disorders
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
CA2741029A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2544852C2 (ru) 2009-10-14 2015-03-20 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
WO2016191316A1 (en) * 2015-05-22 2016-12-01 Stem Cell Theranostics, Inc. Modulation of drug-induced cardiotoxicity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
UA47467C2 (uk) * 1996-05-07 2002-07-15 Файзер Інк. Тригідрат мезилату 5-(2-(4-(1,2-бензизотіазол-3-іл)-1-піперазиніл)етил)-6-хлор-1,3-дигідро-2(1н)-індол-2-ону (зипразидону), фармацевтична композиція та спосіб лікування психічних розладів
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
IL125951A (en) * 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) * 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
AU3329500A (en) * 1999-03-30 2000-10-23 Lion Corporation Hairdye composition of single preparation type containing an oxidase
CA2363942A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
AR044337A1 (es) 2005-09-07
MXPA05012325A (es) 2006-01-30
JP2006528236A (ja) 2006-12-14
US20080269246A1 (en) 2008-10-30
CA2625837A1 (en) 2004-11-25
US20050014764A1 (en) 2005-01-20
CA2525323A1 (en) 2004-11-25
EP1626722A1 (en) 2006-02-22
TW200507847A (en) 2005-03-01
WO2004100956A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
BRPI0419067A (pt) método para aumento da cognição utilizando ziprasidona
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
TN2009000242A1 (en) Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
MY148982A (en) Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals
MA34922B1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
TNSN07148A1 (en) (biphenyl) carboxylic acids and derivatives thereof
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
BRPI0509512A (pt) método de tratar esquizofrenia e/ou anormalidades glicorregulatórias
MX2010006647A (es) Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
MA30592B1 (fr) Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
MA32108B1 (fr) Derives d'indazole
BR0011403A (pt) Processos para a purificação e para a preparação de ácido acrìlico ou ácido metacrìlico
ATE357453T1 (de) Comt-inhibitoren
BRPI0713381A2 (pt) composto, composição farmacêutica, e, método para o tratamento de uma doença
MA28340A1 (fr) Derives de l'acide 7- amino-4- quinolone-3-carboxylique substitues par un groupe cycloalkyle, methode pour leur production et leur utilisation en tant que medicaments
TW200500349A (en) Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
BRPI0408248A (pt) derivados azabicìclicos de piridiloximetila e de benzisoxazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 3A. E 6A. ANUIDADES.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2082 DE 30/11/2010. TEXTO CORRETO: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2082 DE 30/11/2010 E RPI 2090 DE 25/01/2011.